Project Grant R21CA302996
Award Date 5/25/26
Completion Date 4/30/28
Dollars Obligated $409K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
- Federal Grant Award Summary The University of Pittsburgh received a $435,788 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop novel therapeutic approaches targeting mutant isocitrate dehydrogenase (IDH) enzymes in cancer patients. The grant, awarded April 1, 2026, with a completion date of March 31, 2031, supports the discovery and development of active site-directed inhibitors and proteolysis targeting chimeras (PROTACs)...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $657,776 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning August 1, 2025, and extending through May 31, 2030. This award supports the development of highly tumor-selective pan RAS inactivators to address oncogenic RAS-driven cancers, which account for approximately 46% of all human malignancies. The project addresses a significant clinical challenge: while...
- Federal Grant Award Summary The University of Pittsburgh received a $149,804 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) awarded March 1, 2025, with completion scheduled for February 28, 2026. This award supports research investigating the impact of LAG3 (Lymphocyte Activation Gene 3) on CD8+ T cell motility and migration in the context of cancer immunotherapy. The research builds upon preliminary findings demonstrating that...
- Federal Grant Award Summary The University of Pittsburgh received a $408,829 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2025, through May 31, 2027. This award supports the development of positive allosteric modulators (PAMs) targeting XCR1, a chemokine receptor expressed on conventional dendritic cells subtype 1 (CDC1s). The research will utilize DNA-encoded library (DEL) technology and cryo-electron...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $379,644 Project Grant to the University of Pittsburgh under the Cancer Treatment Research program (CFDA 93.395) for the period of June 1, 2026 through May 31, 2028. The project develops cyclic peptide-based adaptors for universal Chimeric Antigen Receptor (CAR) T cell therapy. The research focuses on designing, synthesizing, and testing cyclic peptide adaptors that can program SNAP-CAR (Snap-tag CAR) T cells to...
- Federal Grant Award Summary The University of Pittsburgh received a $658,492 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on March 18, 2026, with completion targeted for February 28, 2031. This award supports research and development of a novel targeted combinatorial therapy for advanced castration-resistant prostate cancer (ACRPC), including castration-resistant prostate cancer-adenocarcinoma (CRPC-ADENO) and neuroendocrine...
- Federal Grant Award Summary The University of Pittsburgh received a $151,040 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded December 12, 2025, with completion targeted for November 30, 2027. This award supports biomedical research training and investigator development focused on understanding the relative and synergistic contributions of programmed cell-death-1 (PD1) and lymphocyte activation gene 3 (LAG3) inhibitory...
- Federal Grant Award Summary The University of Pittsburgh received a $261,662 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded December 1, 2025, with completion targeted for April 16, 2029. This award funds an integrated in silico and in vivo genetic screening research initiative designed to identify subtype-specific genetic dependencies in hepatocellular carcinoma (HCC). The research employs a hybrid computational and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $638,422 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This five-year award supports fundamental research investigating the mechanisms of ovarian cancer metastasis, specifically examining how detachment-sensing proteins, particularly the atypical GTPase RhoV, facilitate peritoneal metastasis in high-grade serous...
- Federal Grant Award Summary The National Cancer Institute awarded The Wistar Institute of Anatomy and Biology a $780,764 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 15, 2026, with completion targeted for March 31, 2031. This research initiative investigates the role of branched-chain amino acid (BCAA) oxidation and signaling pathways in tumor-associated macrophages (TAMs) to enhance anti-tumor immunity in pancreatic ductal adenocarcinoma (PDAC). The...